Spotlight on GA: A bright future with potential treatments
September 16, 2022
According to Rishi P. Singh, MD, family history and lifestyle are key in the development of geographic atrophy.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Therapeutics
Study: Comparing biosimilar of ranibizumab and Lucentis in efficacy and safety for wet AMD
September 20, 2022
The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.
Aflibercept shown to work at higher dose, longer intervals
September 08, 2022
Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
FDA approves ranibizumab-eqrn as a biosimilar product interchangeable with ranibizumab injection for all five indications
August 03, 2022
Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.
Controlling glaucoma: Eye drop therapy reaches posterior ocular tissues
July 22, 2022
A novel eye drop under development may provide neuroprotection to the retinal ganglion cells.
Apellis announces FDA accepts NDA for pegcetacoplan
July 19, 2022
According to the company, pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy secondary to age-related macular degeneration.
Blog: Artificial tear therapy for dry eye disease not quite as simple as it seems
July 18, 2022
Cynthia Matossian, MD, FACS, ABES, explains why eye care professionals should oversee the selection and use of artificial tears for patients with dry eye.
Two-year data confirms faricimab improves vision for patients diagnosed with wet-AMD
July 14, 2022
In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.
Kala Pharmaceuticals completes sale of Eysuvis, Inveltys to Alcon Inc.
July 11, 2022
Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.
Use of aflibercept in the management of diabetic retinopathy
July 08, 2022
Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.